ClinicalTrials.gg
RecruitingNCT07070349Updated Aug 12, 2025

A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors

A Phase 1/2 interventional study of HRS-6213 in Patients With Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the safety, radiation dosimetry, pharmacokinetics, and preliminary diagnostic efficacy of HRS-6213.

02

Conditions studied

  • Patients With Solid Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form; willing and able to follow the study protocol.
  2. For healthy subjects: 18\~28kg/m2
  3. For patients:

    • 0-1
    • Patients with confirmed tumour
    • proposed surgical resection/exploration (including primary or recurrent tumour
    • sufficient organs function.

Exclusion criteria

Exclusion Criteria:

  1. Known severe allergic reactions, or to the test drug or any component of its preparation, such as alcohol allergy or other allergic history that the investigator deems may increase the risk of the trial.
  2. Received the following treatments before administration:

    1. Received radionuclide diagnostic or therapeutic drugs before administration, and less than 10 physical half-lives have elapsed since the last administration.
    2. Used any intravenous iodinated contrast agent within 24 hours before administration, or used any high-density oral contrast agent within 5 days before administration (oral water-based contrast agent is acceptable).
  3. Concurrent infectious diseases
  4. Severe urinary incontinence, hydronephrosis, severe micturition dysfunction.
  5. Concurrent severe active infection requiring intravenous antibiotic treatment within 14 days before administration.
  6. Unexplained fever > 38.5℃ lasting for more than 1 hour during screening or before administration.
  7. Concurrent severe or poorly controlled cardiac diseases or symptoms, including but not limited to: class 2 or higher heart failure, unstable angina, myocardial infarction within 6 months before administration, > 450 msec in males or QTcF > 470 msec in females.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    HRS-6213

    Drug: HRS-6213

Interventions

  • DrugHRS-6213

    HRS-6213 IV administered as imaging agent for PET scan.

06

What researchers measure

Primary outcomes

  1. Phase 1: Incidence of adverse events (AEs) of HRS-6213

    To evaluate the safety and tolerability of HRS-6213.

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  2. Phase 1: Radiation dosimetry

    To evaluate the distribution of radioactivity in tissues and organs, and obtain the accumulation in major organs, time-radioactivity curves, internal radiation absorbed doses of the whole body and major organs of HRS-6213

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  3. Phase 2: With reference to the Standard of Truth (SOT), evaluate the diagnostic efficacy indicators of HRS-6213 PET at the lesion level

    evaluate the diagnostic efficacy indicators of HRS-6213.

    Time frame: rom first dose of study drug to end of treatment (up to approximately 60 days)

Secondary outcomes

  1. Phase 1: Cmax

    To evaluate the PK of HRS-6213

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  2. Phase 1: Biological half-life (t½)

    To evaluate the PK of HRS-6213

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  3. Phase 1: Tmax

    To evaluate the PK of HRS-6213

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  4. Phase 1: urinary cumulative excretion rate

    To evaluate the PK of HRS-6213

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  5. Phase 1: Lesion uptake curve

    Lesion uptake curve of lesions detected by PET scans at different time points HRS-6213.

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  6. Phase 1: Image quality score

    Imaging quality scores of HRS-6213 with Likert image quality rating scale and signal-to-noise ratio.

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  7. Phase 2: The proportion of subjects with changes in disease staging and treatment decisions before and after HRS-6213 PET imaging.

    changes in disease staging and treatment decisions due to diagnostic test.

    Time frame: From first dose of study drug to end of treatment (up to approximately 60 days)

  8. Phase 2: Intra-observer consistency of the diagnosticians' results

    consistency of the diagnosticians' results by investigators.

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

  9. Phase 2:Incidence of adverse events (AEs) of HRS-6213

    To evaluate the safety and tolerability of HRS-6213.

    Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)

07

Study locations

1 of 1 sites recruiting
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Jihui Hao · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jan 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 17, 2025
StartActual
Jul 10, 2025
Primary completionEst.
Jan 2026
CompletionEst.
Mar 2026
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07070349
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Jul 10, 2025
Primary completion
Jan 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Aug 12, 2025

Study contacts

Xiao Chen
Contact
xiao.chen.xc1@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion